SCHEMBL25348758

SCHEMBL25348758

CCOC(=O)c1cc(COCc2ccccc2)c2cccn2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 2/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GAA P10253 2/20 0.42
KMT2A Q03164 2/20 0.42
CFD P00746 1/20 0.41
MAPK1 P28482 1/20 0.41
CSNK1D P48730 1/20 0.41
MAPT P10636 5/20 0.40
KDM4E B2RXH2 2/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PKM P14618 1/20 0.40
MEN1 O00255 1/20 0.40
HSP90AA1 P07900 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25348205 0.82 SPR (0.49) SPRSMN1; SMN2POLBALDH1A1GAA
SCHEMBL22322792 0.78 CHRM1 (0.48) SPRLMNAALDH1A1KMT2AMAPK1
SCHEMBL21858992 0.78 CHRM1 (0.53) SPRSMN1; SMN2ALDH1A1
SCHEMBL18367334 0.75 GAA (0.48) SPRSMN1; SMN2POLBALDH1A1GAA
SCHEMBL3459890 0.75 ADORA3 (0.48) SPRPOLBGAAKMT2AMAPT
SCHEMBL3459620 0.75 MAPT (0.47) SPRPOLBALDH1A1GAAKMT2A
SCHEMBL30540553 0.74 SPR (0.48) SPRSMN1; SMN2POLBLMNAALDH1A1
SCHEMBL20788482 0.74 MAPT (0.58) POLBLMNAALDH1A1GAAKMT2A
SCHEMBL3460031 0.73 SPR (0.47) SPRPOLBALDH1A1GAAKMT2A
SCHEMBL28573813 0.73 SPR (0.47) SPRPOLBGAAKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE, LTD. (KY) 2025-05-22 US disclosed
CN-118696043-A Heterocyclic compounds, compositions thereof and methods of treatment therewith 百济神州有限公司 2024-09-24 CN disclosed
WO-2023151636-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed
WO-2023151641-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH BEIGENE , LTD. (KY) 2023-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163047-A1 HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH NFATC1, GZMB, IFNG SPR 2890/4885SMN1; SMN2 4082/4885POLB 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.